DFNB9 gene therapy (RRGENER Therapeutics/Fudan University/Harvard Medical School)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameDFNB9 gene therapy (RRGENER Therapeutics/Fudan University/Harvard Medical School)
Drug Alias NameAAV1-hOTOFOTOF gene therapy (Shanghai Refreshgene Technology/Fudan University/Harvard Medical School)RRG-003
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionOtoferlin gene transference
TargetsOtoferlin
Therapy Area/IndicationsDeafnessHearing Loss
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesFudan University
China Registration ClassN/A

Develop Information

Active CompaniesFudan UniversityHarvard Medical SchoolShanghai Refreshgene Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsDeafnessHearing Loss
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A